2004, Competition, Healthcare Provider and Specialization

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

OCTOBER 5, 2022

In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs.

Government

Government Specialization Physicians Education

Uri Goren

Cadensee

JULY 20, 2021

48:12 What is Uri Gorenseeing that is special in the Israeli Digital Health ecosystem? 52:21 Uri's opinion about the main problem that needs to be solved for the healthcare market with technology. When he was going through his cancer, he died in 2004. I think vaccines, in most cases, is a special case.

Food and Drug Administration

Food and Drug Administration Doctors Healthcare Healthcare

Pharma Rep Focus

Biogen’s $900 million settlement signals scrutiny on speaker fees

Uri Goren

Stay Connected